KAI-1455

KAI-1455 is a synthetic peptide and selective activator of epsilon protein kinase C (εPKC), developed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting, congenital cardiac defect repair, and hip replacement. It acts by selectively activating εPKC, which plays a key role in cytoprotection during periods of ischemia. Preclinical studies demonstrated that administration prior to an ischemic event can significantly reduce infarct size. The drug was investigated for the prevention of ischemic reperfusion injury and perioperative ischemia but development has been discontinued for cardiovascular disorders[1][2][3][6].